Insights from Industry Innovators
Carey Powers caught up with five innovative companies at this years OIS XIV in San Diego, to discuss the latest advancements in ophthalmology on the OIS podcast.
Topics included touchless laser therapy for presbyopia, extending the duration of intravitreal treatments, next-generation tear fluid testing, and new imaging methodologies for vitreoretinal conditions. Guests include:
🔹Alex Lopez, Chief Commercial Officer – Ace Vision Group
🔹Houman Hamadi, MD, PhD, Co-Founder & Chief Medical Officer – Optigo Biotherapeutics
🔹Leanne Lavriola, DO, MBA, President & CEO – InnSight Technology
🔹Nir Katchinskiy, PhD, CEO & Co-Founder – PulseMedica
Resources:
Ace Vision Group: https://acevisiongroup.com/
Optigo Biotherapeutics: https://www.optigobio.com/
InnSight Technology: https://www.innsightech.com/
PulseMedica: https://www.pulsemedica.com/
Explore More Articles
New-generation software further improves precision of laser scleral microporation
VIENNA — In this Healio Video Perspective from the ESCRS meeting, Luca Gualdi, MD, speaks about the latest advances in laser scleral microporation. Laser scleral microporation (LSM, Ace Vision Group) is a treatment that restores accommodation in presbyopic patients by uncross-linking the scleral tissue that becomes stiff with age. It does so by performing arrays of micropores in …
read moreAce Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
read moreThe Answer for Aging Eyes?
The accommodation mechanism is the core moving “engine” of the eye – responsible for dynamic range of visual focus, as well as hydrodynamic equilibrium and circulatory functions. Doesn’t it seem likely that there would be potential ocular health benefits in rejuvenating rigid ocular tissues? Today, there still is no authentic viable therapeutic to rejuvenate ocular …
read more